Clinical Trials on Corticobasal Syndrome

Total 33803 results

M.D. Anderson Cancer Center

Completed

Treatment of Myelodysplastic Syndrome (MDS) With Cytokine-Immunotherapy for Low-Risk MDS

Myelodysplastic Syndrome

United States
Veeda Oncology
Cephalon

Terminated

A Phase II Trial of Trisenox Plus Thalomid as Treatment in Patients With Myelodysplastic Syndrome

Myelodysplastic Syndrome

United States
Centre Hospitalier Universitaire de Nice

Terminated

A Trial of Bevacizumab in Myelodysplastic Syndromes (Int-1, Int-2 and High Risk According to International Prognostic Scoring System (IPSS)) With Excess of Marrow Blasts

Myelodysplastic Syndromes

France
Fondazione Amelia Scorza Onlus

Unknown

Collection of Biological Data With Potential Prognostic Relevance in Patients With MYELODYSPLASTIC SYNDROMES (O-MDS-Protocol)

Myelodysplastic Syndrome

Italy
Shandong University
National Natural Science Foundation of China

Unknown

Safety and Efficacy Study of Umbilical Cord/Placenta-Derived Mesenchymal Stem Cells to Treat Myelodysplastic Syndromes

Myelodysplastic Syndromes

China
medac GmbH

Completed

Treosulfan Based Conditioning Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome

Finland
Fundacion para el Estudio de la Hematologia y Hemoterapia...

Terminated

Prospective, Multicenter, Open Label and Single-arm Study of Darbepoetin Alfa for Anemia in Myelodisplastic Syndrome Patients.

Myelodysplastic Syndrome

Spain
Telik

Completed

Study of TLK199 HCl Liposomes for Injection in Myelodysplastic Syndrome

Myelodysplastic Syndromes

United States
National Institutes of Health Clinical Center (CC)

Completed

A Randomized Trial of Antithymocyte Globulin Versus Cyclosporine to Treat the Cytopenia of Myelodysplastic Syndrome

Myelodysplastic Syndromes | Hematologic Diseases

United States
Groupe Francophone des Myelodysplasies

Unknown

Darbepoetin Alpha in Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes

France
Groupe Francophone des Myelodysplasies

Completed

Thalidomide at Low Dose for the Treatment of Patient With Myelodysplastic Syndromes - THAL-SMD-200

Myelodysplastic Syndromes

France
Groupe Francophone des Myelodysplasies

Unknown

Bortezomib and Low Dose Cytarabine in the Treatment of High-Risk Myelodysplastic Syndromes

Myelodysplastic Syndromes

France
Celgene Corporation

Completed

A Study to Access the Safety/Efficacy of Thalidomide in the Treatment of Anemia in Patients With Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States
Shifa Tameer-e-Millat University

Recruiting

Effect of Exercises on Computer Vision Syndrome

Neck Pain | Dry Eye Syndromes | Computer Vision Syndrome | Asthenopia | Head Pain | Eye Strain

Pakistan
Istanbul Physical Medicine Rehabilitation Training...

Completed

Comparison of the Efficacy of Prolotherapy Injection Therapy & Local Anesthetic Injection Therapy.

Myofascial Pain Syndrome of Neck

Turkey
Cantonal Hospital Zenica

Completed

Thyroid Hormone Supplementation in Patients With Septic Shock

Septic Shock | Euthyroid Sick Syndromes

Bosnia and Herzegovina
Shengxian Fan

Completed

An Analysis of the Relative Risk for Low Triiodothyronine Syndrome in Patients With Chronic Radiation Enteritis

The Clinical Incidence of Low Triiodothyronine Syndrome
Instituto de Investigación Biomédica de Salamanca
Carlos III Health Institute

Recruiting

Unified platforM for a Better integRal Evaluation of MyeLodyspLastic Syndromes in SpAin-Strategy for Unraveling Personalized genoMic Medicine in Public heAlth System (UMBRELLA-SUMMA) (UMBRELLA-SUMMA)

Myelodysplastic Syndromes

Spain
Kind Pharmaceuticals LLC

Not yet recruiting

A Study of Efficacy and Safety of AND017 in Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes
National Cancer Institute (NCI)

Recruiting

Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States
Syros Pharmaceuticals

Recruiting

Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome

Myelodysplastic Syndromes

United States, Spain, Belgium, Israel, France, United Kingdom, Austria, Czechia, Italy, Poland, Canada, Hungary, Germany
Gruppo Italiano Malattie EMatologiche dell'Adulto

Recruiting

Molecular Mechanisms of Disease Relapse After Allogenic Stem Cell Transplantation in MDS Patients

Myelodysplastic Syndromes

Italy
Syntrix Biosystems, Inc.
Johns Hopkins University; Mayo Clinic; National Heart, Lung, and Blood Institute... and other collaborators

Recruiting

Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome

Myelodysplastic Syndromes

United States
Centre Hospitalier Universitaire, Amiens

Recruiting

Immunophenotyping of Blood Cells in the Diagnosis Work-up of Myelodysplastic Syndromes (MODIFY)

Myelodysplastic Syndromes

France
The University of Hong Kong

Recruiting

Clinical and Genomic Registry of MDS in Asia

Myelodysplastic Syndromes

Hong Kong
Washington University School of Medicine
Sunesis Pharmaceuticals

Completed

Vosaroxin and Azacitidine in Treating Patients With Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States
Sclnow Biotechnology Co., Ltd.

Suspended

Research for Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-MDS) in the Treatment of Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndromes

China
NYU Langone Health
Perlmutter Cancer Center

Completed

A Phase Ib Study Evaluating the Safety and Tolerability of Vitamin C in Patients With Intermediate or High Risk Myelodysplastic Syndrome With TET2 Mutations

Myelodysplastic Syndromes

United States
Gilead Sciences

Terminated

Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS) (ENHANCE)

Myelodysplastic Syndromes

United States, Spain, Belgium, Australia, France, Hong Kong, Hungary, Finland, New Zealand, Germany, Netherlands, United Kingdom, Italy, Switzerland, Portugal, Canada, Austria, Czechia, Norway, Poland, Turkey
Celgene

Completed

Safety and Efficacy Study of CC-486 in Subjects With Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States, United Kingdom, Australia, Poland, Spain, Belgium, Italy, Germany, France, Canada
Sohag University

Completed

Clinical and Laboratory Parameters of Myelodysplastic Syndromes at Upper Egypt

Myelodysplastic Syndromes

Egypt
National Cancer Institute (NCI)

Active, not recruiting

BMS-986253 in Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States
CrystalGenomics, Inc.

Active, not recruiting

Phase 1/2 Study of CG200745 PPA for Myelodysplastic Syndrome

Myelodysplastic Syndrome

Korea, Republic of
Geron Corporation

Available

Expanded Access for Treatment With Imetelstat

Myelodysplastic Syndromes
Innovent Biologics (Suzhou) Co. Ltd.

Suspended

Safety and Efficacy of IBI188 With Azacitidine in Subjects With Newly Diagnosed Higher Risk MDS

Myelodysplastic Syndromes

China
Karyopharm Therapeutics Inc

Withdrawn

Efficacy & Safety Study of KPT-330 in Erythropoietin-Refractory Lower-Risk Myelodysplastic Syndrome Patients (SIER)

Myelodysplastic Syndrome
SymBio Pharmaceuticals

Completed

Study of SyB C-1101 in Patients With Myelodysplastic Syndrome

Myelodysplastic Syndrome

Japan
Takeda

No longer available

Expanded Access Program With Pevonedistat (Given With Azacitidine) for Adults With Higher-risk Myelodysplastic Syndromes

Myelodysplastic Syndromes
Istituto Clinico Humanitas

Active, not recruiting

GENOMED4ALL: Improving MDS Classification and Prognosis by AI

Myelodysplastic Syndromes

Italy
Celgene

Completed

Non-interventional Study of Lenalidomide in the Clinical Routine Treatment of TD Patients With IPSS Low or Int-1 MDS and Isolated Del(5q) (PASS MDS del5q)

Myelodysplastic Syndrome

Spain, United Kingdom, Denmark, Germany, France, Greece, Italy, Sweden, Belgium, United States, Luxembourg, Norway
University Hospital, Bordeaux

Active, not recruiting

Cohort Study Assessing the Treatment Strategy for High-Risk Myelodysplastic Syndromes in Patients Under 70 (COMYRE)

Myelodysplastic Syndromes

France
Gustavo Rivero
Baylor College of Medicine

Terminated

Sertraline in Treatment of Low-Risk Myelodysplastic Syndrome (SS1)

Myelodysplastic Syndromes

United States
Assiut University

Completed

Mean Platelet Volume and Its Relation to Risk Stratification of Myelodysplastic Syndromes

Myelodysplastic Syndromes
Groupe Francophone des Myelodysplasies

Completed

Intensified Azacitidine in High Risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome

France
MedPacto, Inc.

Completed

Dose Escalation and Proof-of-Concept Studies of Vactosertib (TEW-7197) Monotherapy in Patients With MDS

Myelodysplastic Syndromes

United States
Gruppo Italiano Malattie EMatologiche dell'Adulto

Completed

Observational Evaluation of Infective Risk in Myelodysplastic Syndrome Patients

Myelodysplastic Syndrome

Italy
Genzyme, a Sanofi Company

Completed

Antithymocyte Globulin Compared With Supportive Care in Treating Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes

United States, Canada
Array Biopharma, now a wholly owned subsidiary...

Completed

A Study of ARRY-614 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States
Kura Oncology, Inc.

Terminated

Tipifarnib in Subjects With Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States
Celgene

Completed

Study of Azacitidine in Adult Taiwanese Subjects With Higher-Risk Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes

Taiwan

Clinical Trials on Corticobasal Syndrome

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Netherlands

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations